The chief advantage of ADCs over small-molecule-based therapeutics is that ADCs specifically target only their surface antigens, such as CD19, CD22, CD79b, etc., in B-cell lymphomas. The gene discussed is CD79B; the disease is B-cell non-Hodgkin lymphoma.